[1] Sun J, Zhang D, Li Y. Extracellular vesicles in pathogenesis and treatment of metabolic associated fatty liver disease. Front Physiol, 2022, 13:909518.
[2] Liu XL, Pan Q, Cao HX, et al. Lipotoxic Hepatocyte-Derived Exosomal MicroRNA 192-5p activates macrophages through rictor/akt/forkhead box transcription factor O1 signaling in nonalcoholic fatty liver disease. Hepatology, 2020, 72(2): 454-469.
[3] Hernández A, Geng Y, Sepúlveda R, et al. Chemical hypoxia induces pro-inflammatory signals in fat-laden hepatocytes and contributes to cellular crosstalk with Kupffer cells through extracellular vesicles. Biochim Biophys Acta Mol Basis Dis, 2020, 1866(6): 165753.
[4] Nakao Y, Amrollahi P, Parthasarathy G, et al. Circulating extracellular vesicles are a biomarker for NAFLD resolution and response to weight loss surgery. Nanomedicine, 2021, 36: 102430.
[5] Newman LA, Useckaite Z, Johnson J, et al. Selective isolation of liver-derived extracellular vesicles redefines performance of miRNA biomarkers for non-alcoholic fatty liver disease. Biomedicines. 2022, 10(1):195.
[6] Jiang H, Qian Y, Shen Z, et al. Circulating microRNA-135a-3p in serum extracellular vesicles as a potential biological marker of non-alcoholic fatty liver disease. Mol Med Rep, 2021, 24(1): 498.
[7] Bruno S, Pasquino C, Herrera Sanchez MB, et al. HLSC-derived extracellular vesicles attenuate liver fibrosis and inflammation in a murine model of non-alcoholic steatohepatitis. Mol Ther, 2020, 28(2): 479-489.
[8] Bissonnette J, Altamirano J, Devue C, et al. A prospective study of the utility of plasma biomarkers to diagnose alcoholic hepatitis. Hepatology, 2017, 66(2): 555-563.
[9] Sehrawat TS, Arab JP, Liu M, et al. Circulating extracellular vesicles carrying sphingolipid cargo for the diagnosis and dynamic risk profiling of alcoholic hepatitis. Hepatology, 2021, 73(2): 571-585.
[10] Arab JP, Sehrawat TS, Simonetto DA, et al. An open-label, dose-escalation study to assess the safety and efficacy of IL-22 agonist F-652 in patients with alcohol-associated hepatitis. Hepatology, 2020, 72(2): 441-453.
[11] Nguyen HQ, Lee D, Kim Y, et al. Label-free quantitative proteomic analysis of serum extracellular vesicles differentiating patients of alcoholic and nonalcoholic fatty liver diseases. J Proteomics, 2021, 245: 104278.
[12] Nielsen MC, Andersen MN, Grønbæk H, et al. Extracellular vesicle-associated soluble CD163 and CD206 in patients with acute and chronic inflammatory liver disease. Scand J Gastroenterol, 2020, 55(5): 588-596.
[13] Husa P, Snopkova S, Zavrelova J, et al. Circulating microparticles in patients with chronic hepatitis C and changes during direct-acting antiviral therapy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2021, 165(2): 146-151.
[14] Aydin Y, Koksal AR, Reddy V, et al. Extracellular vesicle release promotes viral replication during persistent HCV infection. Cells, 2021, 10(5): 984.
[15] Ninomiya M, Inoue J, Krueger EW, et al. The exosome-associated tetraspanin CD63 contributes to the efficient assembly and infectivity of the hepatitis B virus. Hepatol Commun, 2021, 5(7): 1238-1251.
[16] Santangelo L, Bordoni V, Montaldo C, et al. Hepatitis C virus direct-acting antivirals therapy impacts on extracellular vesicles microRNAs content and on their immunomodulating properties. Liver Int, 2018, 38(10): 1741-1750.
[17] Nik Mohamed Kamal NNSB, Shahidan WNS. Non-exosomal and exosomal circulatory microRNAs: which are more valid as biomarkers? Front Pharmacol, 2020, 10: 1500.
[18] Weil D, Di Martino V, Mourey G, et al. Small annexin V-positive platelet-derived microvesicles affect prognosis in cirrhosis: a longitudinal study. Clin Transl Gastroenterol, 2021, 12(5): e00333.
[19] Gonzalez E, Azkargorta M, Garcia-Vallicrosa C, et al. Could protein content of urinary extracellular vesicles be useful to detect cirrhosis in alcoholic liver disease? Int J Biol Sci, 2021, 17(8): 1864-1877.
[20] Sun N, Zhang C, Lee YT, et al. HCC EV ECG score: an extracellular vesicle-based protein assay for detection of early-stage hepatocellular carcinoma. Hepatology, 2023, 77(3):774-788.
[21] Shuen TWH, Alunni-Fabbroni M, Öcal E, et al. Extracellular vesicles may predict response to radioembolization and sorafenib treatment in advanced hepatocellular carcinoma: an exploratory analysis from the SORAMIC trial. Clin Cancer Res, 2022, 28(17):3890-3901.
[22] Chen YQ, Zheng L, Zhou J, et al. Evaluation of plasma LC3B+extracellular vesicles as a potential novel diagnostic marker for hepatocellular carcinoma. Int Immunopharmacol, 2022, 108:108760.
[23] Kim SS, Baek GO, Ahn HR, et al. Serum small extracellular vesicle-derived LINC00853 as a novel diagnostic marker for early hepatocellular carcinoma. Mol Oncol, 2020, 14(10): 2646-2659.
[24] Xue X, Zhao Y, Wang X, et al. Development and validation of serum exosomal microRNAs as diagnostic and prognostic biomarkers for hepatocellular carcinoma. J Cell Biochem, 2019, 120(1): 135-142.
[25] Lee YR, Kim G, Tak WY, et al. Circulating exosomal noncoding RNAs as prognostic biomarkers in human hepatocellular carcinoma. Int J Cancer, 2019, 144(6): 1444-1452.
[26] Ghosh S, Bhowmik S, Majumdar S, et al. The exosome encapsulated microRNAs as circulating diagnostic marker for hepatocellular carcinoma with low alpha-fetoprotein. Int J Cancer, 2020, 147(10): 2934-2947.
[27] Yang K, Wang W, Wang Y, et al. Proteomic analysis of serum and serum exosomes, and their application in intrahepatic cholangiocarcinoma. Se Pu, 2021, 39(11): 1191-1202.
[28] Lapitz A, Arbelaiz A, O′Rourke CJ, et al. Patients with cholangiocarcinoma present specific RNA profiles in serum and urine extracellular vesicles mirroring the tumor expression: novel liquid biopsy biomarkers for disease diagnosis. Cells, 2020, 9(3): 721.
[29] Xue XY, Liu YX, Wang C, et al. Identification of exosomal miRNAs as diagnostic biomarkers for cholangiocarcinoma and gallbladder carcinoma. Signal Transduct Target Ther, 2020, 5(1): 77.
[30] Stravitz RT, Bowling R, Bradford RL, et al. Role of procoagulant microparticles in mediating complications and outcome of acute liver injury/acute liver failure. Hepatology, 2013, 58(1): 304-313.
[31] Jiao Y, Lu W, Xu P, et al. Hepatocyte-derived exosome may be as a biomarker of liver regeneration and prognostic valuation in patients with acute-on-chronic liver failure. Hepatol Int, 2021,15(4): 957-969. |
